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Characterization of Patients With Axial Spondyloarthritis 
by Enthesitis Presence: Data from the Corrona Psoriatic 
Arthritis/Spondyloarthritis Registry
Philip J. Mease,1  Mei Liu,2 Sabrina Rebello,2 Winnie Hua,2 Robert R. McLean,2 Esther Yi,3 Yujin Park,3 and 
Alexis Ogdie4
Objective. To compare the characteristics of patients with axial spondyloarthritis (axSpA) who had enthesitis 
versus those without enthesitis.
Methods. This study included adult patients with axSpA enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis 
Registry (March 2013 to August 2018). Enthesitis was assessed at enrollment via the Spondyloarthritis Research 
Consortium of Canada Enthesitis Index. Characteristics were compared between patients with and without enthesitis 
using t tests or Wilcoxon rank-sum tests for continuous variables and χ2 or Fisher exact tests for categorical variables.
Results. Of 477 patients with axSpA, 121 (25.4%) had enthesitis (mean, 3.9 sites) at enrollment. Higher proportions 
of patients with enthesitis were female and had nonradiographic axSpA than those without enthesitis (both P < 0.05). 
Additionally, higher proportions of patients with enthesitis had prior biologic (38.8% vs 27.2%) and conventional 
synthetic disease-modifying antirheumatic drug (csDMARD; 24.8% vs 13.3%) use and were currently receiving a 
combination of biologics and csDMARDs (28.6% vs 18.1%) than those without enthesitis. Patients with enthesitis had 
worse disease activity (tender and swollen joint counts, physician global assessment, Ankylosing Spondylitis Disease 
Activity Score, Bath Ankylosing Spondylitis Disease Activity Index, and Bath Ankylosing Spondylitis Functional Index), 
spinal mobility, and quality of life (pain, fatigue, Health Assessment Questionnaire, and EuroQol visual analog scale 
scores); greater work impairment; and had a history of depression and fibromyalgia than those without enthesitis (all 
P < 0.05).
Conclusion. In this US-based real-world study, enthesitis in patients with axSpA was associated with worse 
disease activity and quality of life than those with no enthesitis.
INTRODUCTION
Spondyloarthritis (SpA) comprises a group of rheumatic 
 diseases that include ankylosing spondylosis (AS), reactive arthri-
tis, psoriatic arthritis (PsA), juvenile SpA, and arthritis and spon-
dylitis associated with inflammatory bowel disease, such as 
 ulcerative colitis and Crohn disease (1). SpA with predominantly 
axial involvement is termed axial SpA (axSpA) and is classified 
into two subgroups based on presence (AS) or absence (non-
radiographic axSpA [nr-axSpA]) of radiographic sacroiliitis (1). 
Enthesitis, defined as inflammation of tendon, ligament, or joint 
capsule insertion sites into bone, or entheses, commonly occurs 
This study was sponsored by Corrona, LLC, and financially supported 
by Novartis. The design and conduct of the study were a collaborative 
effort between Corrona, LLC, and Novartis. Novartis participated in the 
interpretation of data and review and approval of the abstract. Corrona, LLC, 
has been supported through contracted subscriptions in the last 2 years 
by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, 
Crescendo, Eli Lilly and Company, Genentech, Gilead, GlaxoSmithKline, 
Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, 
Pfizer Inc, Regeneron, Roche, Sun, and UCB. Dr. Mease has received research 
grants from Celgene, Novartis, AbbVie, Amgen, Bristol-Myers Squibb, Lilly, 
Pfizer, and UCB. Dr. Ogdie has received grant support from the NIH National 
Institute of Arthritis and Musculoskeletal and Skin Diseases, National Psoriasis 
Foundation, Rheumatology Research Foundation, Pfizer, and Novartis.
1Philip J. Mease, MD, MACR: Swedish Medical Center/Providence St. 
Joseph Health and University of Washington, Seattle, Washington; 2Mei Liu, 
PhD, Sabrina Rebello, MPH, Winnie Hua, MA, MS, Robert R. McLean, DSc, 
MPH: Corrona, LLC, Waltham, Massachusetts; 3Esther Yi, PharmD, Yujin 
Park, PharmD: Novartis Pharmaceuticals Corporation, East Hanover, New 
Jersey; 4Alexis Ogdie, MD, MSCE: University of Pennsylvania, Philadelphia, 
Pennsylvania.
Dr. Mease has received consulting fees from Celgene, Corrona, Novartis, 
AbbVie, Amgen, Bristol-Myers Squibb, Galapagos, Gilead, Janssen, Lilly, 
Merck, Pfizer, Sun, and UCB; and speakers bureau fees from AbbVie, Amgen, 
Bristol-Myers Squibb, Celgene, Genentech, Janssen, Pfizer, and UCB. Dr. 
Ogdie has received consulting fees from Amgen, AbbVie, Bristol-Myers 
Squibb, Celgene, Lilly, Novartis, and Pfizer. No other disclosures relevant to 
this article were reported.
Address correspondence to Philip J. Mease, MD, MACR, Seattle 
Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122. 
E-mail: pmease@philipmease.com.
Submitted for publication March 6, 2020; accepted in revised form 
March 23, 2020.
MEASE ET AL 450       |
in patients with SpA (2). Enthesitis may be among the first symp-
toms of SpA (3) and was identified as a unique feature of SpA 
that could differentiate this group of rheumatic diseases from 
rheumatoid arthritis (RA) (4). Enthesitis predominantly occurs in 
extra-articular structures prone to inflammation in SpA diseases, 
whereas RA is characterized by intra-articular inflammation of 
the synovial membrane; both enthesitis and synovitis can occur 
simultaneously or independently of one another (2).
Enthesitis is a key clinical feature of SpA, with or without 
axial involvement (5). Among patients with AS and nr-axSpA, 
the prevalence of enthesitis is reportedly 34% to 74% (6-8) and 
35.4% (7), respectively. However, enthesitis is often underdi-
agnosed, and quantification of peripheral enthesitis in routine 
clinical practice lacks specificity and sensitivity (9,10). Enthesi-
tis is commonly observed in the lower extremities of patients 
with SpA, particularly the heel (11). In addition to the Achilles 
and plantar fascia insertions, other frequently observed sites of 
enthesitis include muscle attachments to the greater and lesser 
trochanters, insertion of the quadriceps tendon at the upper 
patellar pole, and insertions of the flexor and extensor tendons 
at the phalanges (9,11).
Clinical evaluation of enthesitis is challenging. Correlation 
between clinical examination of tenderness at entheseal insertion 
sites and imaging techniques for evidence of entheseal inflamma-
tion is low (12). In addition, enthesis sites are not readily acces-
sible to biopsy for verification of inflammatory change, unlike the 
synovium, skin, or gut; hence, physical examination of entheseal 
insertion sites may not reflect true inflammatory change but could 
reveal variable pain thresholds and the phenomenon of central 
sensitization (13). Despite its frequent occurrence among patients 
with axSpA and its correlation with disease severity, enthesitis is 
primarily evaluated as a secondary endpoint in randomized clinical 
trials or not evaluated at all (14-16).
There are limited real-world studies on the characteristics of 
patients with axSpA and enthesitis. Additionally, relatively little is known 
about the impact of enthesitis on these patients. In this US-based 
study, we sought to compare the characteristics of patients with 
axSpA who had physical evidence of enthesitis with those of patients 
without enthesitis. Because imaging methods were not used to verify 
the presence of enthesitis, the results reported in our study describe 
the characteristics and impact of clinical enthesitis.
METHODS
Data source. The Corrona PsA/SpA Registry is a large, 
independent, prospective, observational cohort of patients 
diagnosed with PsA or SpA by a rheumatologist. Patients were 
recruited from 44 private and academic practice sites across 27 
states in the United States, with 46 participating rheumatolo-
gists. As of June 2019, data on approximately 3939 patients 
with PsA/SpA had been collected. The Corrona PsA/SpA Reg-
istry includes information on 15 806 patient visits and approx-
imately 8423 patient-years of follow-up, with a mean patient 
follow-up of 2.9 years (median, 2.4 years).
All participating investigators were required to obtain full board 
approval for conducting noninterventional research with a limited 
data set involving human participants. The Corrona PsA/SpA Reg-
istry and its investigators have been reviewed and approved by a 
central institutional review board (IRB; New England Independent 
Review Board No. 120160070). For academic investigative sites 
that did not receive a waiver to use the central IRB, approval was 
obtained from the respective governing IRBs. All research was 
conducted in compliance with the current (2013) Declaration of 
Helsinki. All registry participants were required to provide written 
informed consent and authorization prior to participating.
Study design and population. This cross-sectional 
observational study included all patients aged 18 years or older 
enrolled in the Corrona PsA/SpA Registry between March 2013 
and August 2018 who had rheumatologist-diagnosed axSpA (AS 
or nr-axSpA) according to the Assessment of Spondyloarthritis 
International Society classification criteria (17,18). Patients who 
had a concomitant PsA diagnosis were excluded.
Patients were stratified by the presence or absence of clin-
ical enthesitis at registry enrollment. Patients were classified as 
having enthesitis (yes/no) at any site using the Spondyloarthritis 
Research Consortium of Canada (SPARCC) Enthesitis Index, 
a measure of enthesitis based on presence of tenderness at 16 
entheseal sites (19). The SPARCC Enthesitis Index assesses nine 
bilateral sites: medial epicondyle, lateral epicondyle, supraspina-
tus insertion into greater tuberosity of humerus, greater trochanter, 
quadriceps insertion into superior border of patella, patellar liga-
ment insertion into inferior pole of patella or tibial tubercle, Achil-
les tendon insertion into calcaneum, and plantar fascia insertion 
into calcaneum. For scoring purposes, the inferior patella and tib-
ial tuberosities were considered one site due to their anatomical 
proximity. Tenderness was recorded as present (ie, one) or absent 
(ie, zero) at each site. The sites were summed with the overall 
score ranging from 0 to 16; a score of 0 is indicative of absence 
of enthesitis, whereas patients with a score greater than 0 were 
classified as having enthesitis.
Outcomes and assessments. Data were collected at 
the registry enrollment visit and included patient demographics 
(age, sex, race/ethnicity, marital status, and patient-reported 
work status), clinical characteristics (physician-reported history 
of comorbidities and disease and symptom duration), treatment 
profiles (prior and current biologic and conventional synthetic 
disease-modifying antirheumatic drug [csDMARD] use), dis-
ease activity measures (Ankylosing Spondylitis Disease Activity 
Score [ASDAS], Bath Ankylosing Spondylitis Disease Activity 
Index [BASDAI], Bath Ankylosing Spondylitis Functional Index 
[BASFI], C-reactive protein [CRP] level, erythrocyte sedimentation 
rate [ESR], tender joint count [TJC], swollen joint count [SJC], 
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SPARCC Enthesitis Index, dactylitis count, and physician global 
assessment), quality of life measures (patient global assessment 
visual analog scale [VAS], patient-reported pain and fatigue, 
Health Assessment Questionnaire Disability Index [HAQ-DI], HAQ 
for the Spondyloarthropathies [HAQ-S] (20), EuroQol Quality of 
Life VAS [EQ-VAS], and EuroQol 5-dimension scale [EQ-5D]), 
and work productivity measures (Work Productivity and Activity 
Impairment questionnaire).
Moderate positive correlations between obesity or higher 
body mass index (BMI) and enthesitis counts in patients with 
axSpA and PsA have been observed in previous studies (21-24). 
To explore a potential relationship between obesity and enthesitis 
at specific sites in our study population, we evaluated the preva-
lence of enthesitis at each SPARCC enthesitis site among patients, 
with enthesitis stratified by BMI category (normal/underweight, 
BMI < 25 kg/m2; overweight, BMI 25 to < 30 kg/m2; obese, BMI 
≥ 30 kg/m2).
Data analysis. Means and frequencies of characteristics 
in all patients with positive enthesitis scores were compared with 
those in patients without positive enthesitis scores (reference 
group) using χ2 or Fisher exact tests for categorical variables and 
t tests or Wilcoxon rank-sum tests for continuous variables.
RESULTS
Baseline patient demographics, clinical character-
istics, and treatment profiles. A total of 477 patients with 
axSpA met the inclusion criteria. The majority of patients were 
white, overweight (mean BMI, 29 kg/m2), worked full time, and 
had private insurance (Table 1). Overall, 121 patients (25.4%) had 
enthesitis and 356 (74.6%) did not. The prevalence of enthesitis 
at each site (mean, 3.9 sites) among patients with enthesitis is 
shown in Figure 1). Enthesitis was most prevalent in the greater 
trochanter (43.8%) followed by the lateral epicondyle (43.0%) and 
supraspinatus insertion into the greater tuberosity of the humerus 
(34.7%). There was no significant relationship between BMI cate-
gories and presence of enthesitis (Supplementary Table 1).
Higher proportions of patients with enthesitis were female 
and had nr-axSpA than those without enthesitis (both P < 0.05; 
Table 1). Patients with enthesitis were more likely to have a his-
tory of depression, serious infections, and fibromyalgia than 
those without enthesitis (all P < 0.05; Table 2). With regard to 
Table 1. Baseline demographics of patients with axSpA at 











Nonradiographic axSpA, n (%) 34 (28.1) 56 (15.7) <0.01
Age, mean (SD), yearsc 47.3 (13.1) 47.3 (14.1) 0.99
Female, n (%) 61 (50.4) 112 (31.9) <0.01
White, n (%) 105 (88.2) 319 (92.7) 0.16
Attended college/university, n (%) 92 (76.7) 236 (67.0) 0.09
Private insurance, n (%) 96 (82.1) 276 (81.9) 0.12
Work status, n (%) n = 121 n = 351 0.30
Full time 69 (57.0) 214 (61.0)
Part time 7 (5.8) 22 (6.3)
Disabled 24 (19.8) 42 (12.0)
Retired 12 (9.9) 44 (12.5)
Other 9 (7.4) 29 (8.3)
BMI, mean (SD), kg/m2 29.9 (6.9) 29.8 (6.8) 0.83
BMI (in kg/m2) categories, n (%) n = 120 n = 345 0.46
Normal/underweight (<25) 33 (27.5) 86 (24.9)
Overweight (25 to <30) 33 (27.5) 116 (33.6)
Obese (≥30) 54 (45.0) 143 (41.4)
Abbreviation: axSpA, axial spondyloarthritis; BMI, body mass index.
aAll values were calculated based on available data and had less than 
20% missing data. 
bP value for comparison between patients with versus those without 
enthesitis. The Wilcoxon rank-sum test was used for continuous 
variables, whereas the χ2 test was used for categorical variables. For 
variables where more than 20% of the cells had expected counts less 
than five, the Fisher exact test was used. 
ct test for age comparison between pairs of groups. 
Figure 1. Distribution of enthesitis sites among patients with axial spondyloarthritis. aPercentages listed are a total of the left and right affected 
sites. bFor scoring purposes, the inferior patella and tibial tuberosities are considered one site due to their anatomical proximity.
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treatment, higher proportions of patients with enthesitis had a 
history of prior biologic (38.8% vs 27.2%) and csDMARD (24.8% 
vs 13.2%) use than those without enthesitis (both P < 0.05; 
Table 2). The proportion of patients currently receiving biologic 
therapy was comparable between groups. However, among 
patients currently receiving a tumor necrosis factor inhibitor 
(TNFi), a higher proportion of patients with enthesitis were receiv-
ing a TNFi in combination with csDMARDs than those without 
enthesitis (28.6% vs 18.1%).
Baseline disease activity measures. Patients with 
enthesitis had worse disease activity than those without enthesi-
tis, including higher mean TJC (8.2 vs 1.3) and SJC (1.3 vs 0.5); 
higher ASDAS (2.9 vs 2.5), BASDAI (5.3 vs 4.1), BASFI (4.5 vs 
3.3), and physician global assessment (36.6 vs 23.5) scores; 
and more restricted spinal mobility as measured by mean lateral 
lumbar flexion (28.1 vs 21.5 cm) (all P < 0.05; Table 3). Additionally, 
patients with enthesitis had lower CRP levels (6.9 vs 10.4 mg/L) 
and ESR (14.2 vs 15.5 mm/h) than those without enthesitis, but 
these differences were not statistically significant (Table 3).
Baseline patient-reported outcome measures and 
work productivity. Patients with enthesitis had worse quality 
of life than those without enthesitis, including higher mean pain 
(57.5 vs 43.5), fatigue (56.5 vs 45.0), HAQ-DI (0.9 vs 0.6), and 
HAQ-S (0.9 vs 0.6) scores; additionally, they had a lower EQ-VAS 
score at enrollment (59.7 vs 66.4), indicating a worse health state 
(all P < 0.01; Table 4). With regard to work productivity and activ-
ity impairment, patients with enthesitis had a significantly greater 
Table 2. Baseline clinical characteristics and treatment history of 











Symptom duration, mean (SD), y 17.3 (13.1) 16.8 (11.8) 0.67
Disease duration, mean (SD), y 8.2 (10.3) 10.2 (10.7) 0.09
History of comorbidities, n (%)
Cardiovascular disease 56 (46.3) 140 (39.3) 0.18
Hypertension 37 (30.6) 109 (30.6) 0.99
Depression 29 (24.0) 53 (14.9) 0.02
Hyperlipidemia 21 (17.4) 52 (14.6) 0.47
Uveitis 13 (10.7) 40 (11.2) 0.88
Metabolic syndrome 9 (7.4) 27 (7.6) 0.96
Psoriasis 7 (5.8) 22 (6.2) 0.88
Diabetes mellitus 11 (9.1) 20 (5.6) 0.18
Ulcerative colitis 3 (2.5) 18 (5.1) 0.31
Serious infections 12 (9.9) 16 (4.5) 0.03
Any cancer (excluding NMSC) 5 (4.1) 16 (4.5) 0.87
Crohn disease 6 (5.0) 14 (3.9) 0.63
Fibromyalgia 11 (9.1) 11 (3.1) 0.01
Anxiety 6 (5.0) 7 (2.0) 0.08
History of prior biologic use, n (%) 47 (38.8) 97 (27.2) 0.02
No. of prior biologics used, n (%) 0.01
0 74 (61.2) 259 (72.8)
1 26 (21.5) 68 (19.1)
≥2 21 (17.4) 29 (8.1)
History of prior csDMARD use,  
 n (%)
30 (24.8) 47 (13.2) <0.01
No. of prior csDMARDs used,  
 n (%)
0.01
0 91 (75.2) 309 (86.8)
1 22 (18.2) 37 (10.4)
≥2 8 (6.6) 10 (2.8)
Current biologic use, n (%) 84 (69.4) 237 (66.6) 0.56
TNFi use 0.05
Monotherapy 55 (71.4) 185 (81.9)
Combination therapy 22 (28.6) 41 (18.1)
Non-TNFi use 0.47
Monotherapy 6 (100) 6 (75)
Combination therapy 0 2 (25)
Current overall csDMARD use,  
 n (%)c
34 (28.1) 72 (20.2) 0.07
Current csDMARD use only  
 (without biologic or  
 tsDMARD use), n (%)
12 (9.9) 30 (8.4) 0.62
Abbreviation: axSpA, axial spondyloarthritis; csDMARD, conventional 
synthetic disease-modifying antirheumatic drug; NMSC, nonmel-
anoma skin cancer; TNFi, tumor necrosis factor inhibitor; tsDMARD, 
targeted synthetic disease-modifying antirheumatic drug.
aAll values were calculated based on available data and had less than 
20% missing data. 
bP value for comparison between patients with versus those without 
enthesitis. The Wilcoxon rank-sum test was used for continuous 
variables, whereas the χ2 test was used for categorical variables. For 
variables where more than 20% of the cells had expected counts less 
than 5, the Fisher exact test was used. 
cA patient may be on multiple csDMARDs. 
Table 3. Baseline disease activity measures in patients with axSpA 











ASDAS 2.9 (0.9) 2.5 (1.2) <0.01
BASDAI (0-10) 5.3 (2.2) 4.1 (2.4) <0.01
BASFI (0-10) 4.5 (2.8) 3.3 (2.7) <0.01
Tender joint count (0-68) 8.2 (10.8) 1.3 (4.2) <0.01
Swollen joint count (0-66) 1.3 (3.3) 0.5 (2.0) <0.01
Dactylitis, n (%) 4 (3.3) 7 (2.0) 0.40
Dactylitis (1-20) 2.0 (2.0) 3.6 (3.9) 0.35
SPARCC Enthesitis Index (1-16) 3.9 (2.9) 0 …
Inflammatory back pain, n (%) 78 (64.5) 205 (57.6) 0.18
Lateral lumbar flexion (average 
of left and right), cm
28.1 (21.1) 21.5 (18.8) 0.01
CRP, mg/L 6.9 (7.0) 10.4 (24.1) 0.32
ESR, mm/h 14.2 (16.4) 15.5 (18.9) 0.84
Physician global assessment 36.6 (21.9) 23.5 (21.9) <0.01
Abbreviation: ASDAS, Ankylosing Spondylitis Disease Activity Score; 
axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis 
Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional 
Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; 
SPARCC, Spondyloarthritis Research Consortium of Canada.
aAll values were calculated based on available data and are presented 
as mean (SD) unless otherwise stated and had less than 20% missing 
data except for ESR and CRP. 
bP value for comparison between patients with versus those without 
enthesitis. The Wilcoxon rank-sum test was used for continuous 
variables, whereas the χ2 test was used for categorical variables. For 
variables where more than 20% of the cells had expected counts less 
than 5, the Fisher exact test was used. 
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percentage of impairment while working (38.3% vs 25.3%), 
percentage of overall work impairment (41.4% vs 27.6%), and 
percentage of activity impairment (49.8% vs 35.6%) than those 
without enthesitis (all P < 0.01).
DISCUSSION
In this US-based real-world study of patients with axSpA, the 
presence of clinical enthesitis was associated with higher disease 
activity and worse quality of life than the absence of enthesitis. 
We also found that patients with enthesitis were more likely to be 
receiving combination therapy, further suggesting that this pop-
ulation had more severe or burdensome disease. These results 
are consistent with previous studies showing that presence of 
enthesitis in patients with axSpA is correlated with increased dis-
ease severity and poorer quality of life (25-27). Additionally, con-
sistent with previous reports (27-29), we observed more frequent 
enthesitis among female patients (50%) versus male patients 
(32%). Presence of enthesitis in patients with PsA has been linked 
to axial and peripheral joint damage, likelihood of developing joint 
ankyloses, overall higher disease activity, more pain, worse qual-
ity of life and functional status, sleep disturbance, and patient-re-
ported pain and fatigue (30-32). Additionally, in PsA, enthesitis has 
been regarded as a predictor of poor disease outcomes and may 
represent a lower probability of achieving remission and low dis-
ease activity (22,30).
The higher prevalence of pain or tenderness at entheseal 
sites among female patients with axSpA may contribute to the 
greater disease burden in female than in male patients, despite 
slower radiographic progression in female patients (27-29). How-
ever, in painful chronic disorders, pain can result not only from 
inflammation and mechanical irritation but from a combination 
of mechanisms, including central sensitization, which is defined as 
amplification of neural signaling that leads to pain hypersensitivity 
(33). Central sensitization contributes to the pain hypersensitiv-
ity phenotype of several disorders, including fibromyalgia, which 
represents a state of persistent central sensitization (13,33). The 
American College of Rheumatology introduced fibromyalgia clas-
sification criteria in 1990 based on the scoring of 11 out of 18 ten-
der points (34); these sites overlap with those often assessed for 
enthesitis (35). Subsequent iterations of the criteria have removed 
the tender points assessment, but evaluation of tender points is 
still commonly performed in clinical practice (36). Because central 
pain sensitization likely occurs in some patients with axSpA and 
is associated with higher disease activity (37), patient-reported 
outcome measures may be amplified by presence of fibromy-
algia, which can occur along with axSpA. As in our study, the 
proportion of women with fibromyalgia in previous studies of 
patients with axSpA was higher than that of men (13). Because 
enthesitis was defined in our study as presence of tenderness 
at 18 entheseal points based on physical examination without 
ultrasound or magnetic resonance imaging (MRI) corroboration 
of inflammation, the difference in frequency between men and 
women may partially reflect a higher prevalence of central sensiti-
zation in women, which correlated with symptoms such as higher 
TJC, depression, and fatigue. Therefore, distinguishing fibromy-
algia from axSpA is important and may be addressed using cur-
rently available patient-reported outcome tools for fibromyalgia, 
such as the Widespread Pain Index and Symptom Severity Score 
or the Fibromyalgia Rapid Screening Tool (36). However, it may 
be challenging to differentiate entheseal site tenderness due to 
inflammatory enthesitis from tenderness due to central sensitiza-
tion using only clinical examination; thus, more specific tools for 
diagnosis of fibromyalgia or central sensitization are needed, such 
as validated questionnaires as mentioned above and/or advanced 
imaging techniques, including ultrasound or MRI of the entheses, 
neuroimaging techniques, or quantitative sensory testing (13).
Because enthesitis may be one of the pivotal pathologi-
cal processes in SpA associated with poor disease outcomes 
(30,38), detection of early enthesitis lesions may be critical for 
SpA diagnosis. MRI has shown that extracapsular inflammation 
of joints represents enthesitis with varying extents of soft tissue 
Table 4. Baseline patient-reported outcome measures in patients 











Patient pain (VAS 0-100) 57.5 (26.7) 43.5 (29.5) <0.01
Patient fatigue (VAS 0-100) 56.5 (27.5) 45.0 (28.6) <0.01
Patient global assessment  
 (VAS 0-100)
49.8 (29.7) 54.1 (32.9) 0.56
HAQ-DI (0-3) 0.9 (0.7) 0.6 (0.6) <0.01
HAQ-S (0-3) 0.9 (0.7) 0.6 (0.6) <0.01
EQ-5D (0-1) 0.7 (0.2) 0.7 (0.2) <0.01
EQ (VAS 0-100): patient  
 health today
59.7 (22.7) 66.4 (22.0) <0.01
WPAI-GH domains
% Work time missed 9.0 (18.8) 5.8 (16.8) 0.06
% Impairment while  
 working
38.3 (27.4) 25.3 (24.4) <0.01
% Overall work impairment 41.4 (29) 27.6 (26.6) <0.01
% Activity impairment 49.8 (29.5) 35.6 (29.3) <0.01
Current employment, n (%) 75 (63.0) 241 (68.7) 0.26
Morning stiffness, n (%) n = 117 n = 318 0.72
<30 min 28 (23.9) 71 (22.3)
≥30 min 89 (76.1) 247 (77.7)
Abbreviation: axSpA, axial spondyloarthritis; EQ-5D, EuroQol 
5-dimension questionnaire; HAQ-DI, Health Assessment Ques-
tionnaire Disability Index; HAQ-S, Health Assessment Questionnaire 
for the Spondyloarthropathies; VAS, visual analog scale; WPAI-GH, 
Work Productivity and Activity Impairment Questionnaire-General 
Health.
aAll values were calculated based on available data and are presented 
as mean (SD) unless otherwise stated and had less than 20% missing 
data except for patient global assessment, HAQ-DI, HAQ-S, and 
WPAI-GH1 to WPAI-GH3. 
bP value for comparison between patients with versus those without 
enthesitis. The Wilcoxon rank-sum test was used for disease activity 
measurements, whereas the χ2 test was used for categorical 
variables. 
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and bone marrow edema (39,40). Recently, Poggenborg and col-
leagues demonstrated the utility of whole-body MRI in the detec-
tion of subclinical axial and peripheral enthesitis (41). Detection of 
enthesitis using ultrasound has also been useful, particularly for 
early diagnosis of SpA (42).
Several indices are available for clinical measurement of 
inflammatory activity and treatment response of enthesitis in 
axSpA and peripheral SpA. The Maastricht Ankylosing Spon-
dylitis Enthesitis Score (MASES), University of California, San 
Francisco Index, and Berlin Index have been used in axSpA 
studies (43-45). MASES was initially developed for identifica-
tion of entheses specific for axial disease in AS (46) and has 
performed well in many AS and axSpA trials (45,47,48). The 
SPARCC Enthesitis Index was initially developed for use in both 
axial and peripheral SpA, including PsA (19). Although it has 
principally been used in PsA and has not been used in axSpA 
clinical trials, we have successfully used the SPARCC Enthesi-
tis Index for enthesitis evaluation in previous studies of patients 
with axSpA (30,49-51).
The SPARCC Enthesitis Index has been used in several PsA 
clinical trials with success (52-54). An additional index, the Leeds 
Enthesitis Index (LEI), was developed for enthesitis assessment 
in PsA (55). In the ABILITY-2 trial, which assessed the efficacy of 
adalimumab in patients with peripheral SpA, the LEI, SPARCC, 
and MASES indices were compared for their discriminatory 
capacity in assessing enthesitis and treatment response; the LEI 
and SPARCC Enthesitis Index outperformed the MASES, most 
likely because the MASES primarily evaluates axial sites, whereas 
the LEI and SPARCC Enthesitis Index evaluate more peripheral 
sites (46).
This study has some limitations that should be considered. 
Patients enrolled in this study are routinely seen and treated by 
rheumatologists voluntarily participating in the Corrona PsA/SpA 
Registry and may not be representative of all US patients with 
axSpA. Because presence of enthesitis in our study was based on 
physical examination without imaging corroboration, we cannot 
truly distinguish between central sensitization, as characterized by 
tender entheseal sites, and enthesitis. Accordingly, our findings 
describe features and impact of clinical enthesitis. Additionally, the 
presence of depression and fibromyalgia was based on investi-
gator judgement and was not objectively measured. Going for-
ward, the Corrona Registry will be incorporating the Widespread 
Pain Index and Symptom Severity Scale, a validated quantitative 
tool to measure central sensitization (36,56), to provide a more 
objective assessment of the presence and impact of central sen-
sitization in future analyses. All comparisons were descriptive; 
no adjustments were made to account for differences in patient 
characteristics, such as age and sex, which may have influenced 
the other differences observed between patients with and those 
without enthesitis.
In conclusion, enthesitis was associated with greater over-
all burden of axSpA, including worse disease activity and quality 
of life. Enthesitis may represent the primary underlying process 
for SpA diseases, such as axSpA. Therefore, identification, eval-
uation, and management of enthesitis is critical to ameliorate the 
overall burden of disease. Additionally, more research is needed 
to guide treatment options specific to enthesitis and to better dis-
criminate between enthesitis and central sensitization.
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